Akademik Veri Yönetim Sistemi
6th Organic Chemistry Congress with International Participation, Eskişehir, Türkiye, 10 Eylül - 13 Aralık 2025, ss.67, (Özet Bildiri)
Neurodegenerative diseases are disorders of the central nervous system that lead to progressive loss of nerve cells and
are characterized by severe cognitive dysfunction. In diseases such as Alzheimer’s disease, the most common form of
dementia, losses occur in basic cognitive processes such as memory and learning. According to the cholinergic hypothesis,
one of the main underlying causes of these disorders is the decrease in acetylcholine levels in the brain and loss of function
of cholinergic neurons [1]. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), enzymes that hydrolyse
acetylcholine, play an important role in this process. In this study, therapeutic approaches for the inhibition of AChE and
BuChE enzymes were investigated and the potential inhibitory effects of eugenol carbamate derivatives on these enzymes
were examined [2]. Eugenol, a volatile phenolic bioactive compound obtained from clove, attracts attention in the treatment
of neurodegenerative diseases due to its low toxicity, few side effects, ability to cross the blood-brain barrier and modulate
neuronal signalling pathways. The effect of pharmacological derivatives developed on the basis of eugenol, a natural product
known for its antimicrobial, anti-inflammatory, antioxidant and anticancer properties, on the activity of these enzymes
was evaluated [3]. This study provides an important perspective that eugenol carbamate derivatives can be considered as a
promising strategy for the treatment of neurodegenerative diseases.